| Attending joint formulation meetings on pharmaceuticals and special medical materials. | Рак
> Рак: большинство видов | Регуляторное партнёрство
> Работа с регулирующими органами | 100 000 | National | Sometimes | 119017792133 |
| At year-end, regulatory authorities, cancer patient advocacy groups, and clinical physicians are invited to review the NHI [全民健康保險 – National Health Insurance] reimbursement policies for that year. | Рак
> Рак: большинство видов | Регуляторное партнёрство
> Работа с регулирующими органами | 5 000 | National | Sometimes | 119022421395 |
| Convene an annual year-end review bringing together regulatory authorities, cancer patient advocacy organisations, and clinical physicians to evaluate the NHI reimbursement policies for that calendar year. Patient advocacy groups present on unmet patient needs, clinicians conduct a cancer-type-specific assessment of the gaps between Taiwan's NHI [全民健康保險 – National Health Insurance] reimbursement coverage and oncology treatment guidelines, and dialogue is facilitated with the regulatory authorities. | Рак
> Рак: большинство видов | Регуляторное партнёрство
> Участвовать в оценке медицинских технологий (HTA) и проверках возмещения расходов | 5 000 | National | Sometimes | 119022421395 |
| We communicate patient needs to the National Health Insurance Administration in order to improve patient access to treatment. | Нервно-мышечный
> Спинальная мышечная атрофия (СМА) | Регуляторное партнёрство
> Участвовать в оценке медицинских технологий (HTA) и проверках возмещения расходов | 100 | National | Regularly | 119053648739 |
| Convene an annual year-end review bringing together regulatory authorities, cancer patient advocacy organisations, and clinical physicians to evaluate the NHI reimbursement policies for that calendar year. Patient advocacy groups present on unmet patient needs, clinicians conduct a cancer-type-specific assessment of the gaps between Taiwan's NHI [全民健康保險 – National Health Insurance] reimbursement coverage and oncology treatment guidelines, and dialogue is facilitated with the regulatory authorities. | Рак
> Рак: большинство видов | Регуляторное партнёрство
> Участвовать/проводить встречи с политиками/регуляторами | 5 000 | National | Sometimes | 119022421395 |
| At year-end, regulatory authorities, cancer patient advocacy groups, and clinical physicians are invited to review the NHI [全民健康保險 – National Health Insurance/Taiwan] reimbursement policies for that year. | Рак
> Рак: большинство видов | Регуляторное партнёрство
> Участвовать/проводить встречи с политиками/регуляторами | 5 000 | National | Sometimes | 119022421395 |
| ... Since 2025, the government [in Taiwan] has also begun implementing its Cancer New Drug Fund policy, and our organisation is recognised as one of 13 patient advocacy groups whose efforts contributed to that successful outcome. | Рак
> Рак: большинство видов | Влияние на политику и законодательство
> Влияние на политику и законодательство в сфере здравоохранения | 10 000 | National | Sometimes | 119055308347 |
| With regard to pricing, we have not had the opportunity to participate in discussions, as prices are largely determined by pharmaceutical companies' global headquarters, with patient advocacy groups afforded no meaningful role in the process. Nevertheless, we actively present patients' clinical medication needs to the government in cases where reimbursement under Taiwan's NHI [全民健康保險 – National Health Insurance] is unavailable, with the aim of securing alternative funding mechanisms to support cancer patients — such as a dedicated cancer medicines fund. | Рак
> Рак: большинство видов | Влияние на политику и законодательство
> Участвовать в публичных слушаниях и консультациях | 10 000 | National | Sometimes | 119055325391 |
| To advocate for the expansion of reimbursement coverage for new medicines to encompass broader therapeutic indications. | Общее состояние здоровья
> Оказание медицинской помощи | Пропаганда доступного ценообразования
> Выступать за справедливое ценообразование на лекарства | 5 000 | National | Sometimes | 119051396882 |
| We are advocating for the inclusion of immunotherapy for early-stage triple-negative breast cancer patients within the reimbursement coverage of the National Health Insurance scheme. | Рак
> Рак: молочная железа | Пропаганда доступного ценообразования
> Отстаивание включения продукта в списки возмещения/национальные формуляры | 10 000 | National | Regularly | 119016883314 |
| To advocate for the expansion of reimbursement coverage for new medicines to encompass broader therapeutic indications. | Общее состояние здоровья
> Оказание медицинской помощи | Пропаганда доступного ценообразования
> Отстаивание включения продукта в списки возмещения/национальные формуляры | 5 000 | National | Sometimes | 119051396882 |
| Advocating for the expansion of reimbursement coverage for new medicines to encompass broader indications. | Рак
> Рак: нейроэндокринный (НЭО) | Пропаганда доступного ценообразования
> Отстаивание включения продукта в списки возмещения/национальные формуляры | 100 | National | Sometimes | 119051407743 |
| With regard to pricing, we have not had the opportunity to participate in discussions, as prices are largely determined by pharmaceutical companies' global headquarters, with patient advocacy groups afforded no meaningful role in the process. Nevertheless, we actively present patients' clinical medication needs to the government in cases where reimbursement under Taiwan's NHI [全民健康保險 – National Health Insurance] is unavailable, with the aim of securing alternative funding mechanisms to support cancer patients — such as a dedicated cancer medicines fund. | Рак
> Рак: большинство видов | Пропаганда доступного ценообразования
> Отстаивание включения продукта в списки возмещения/национальные формуляры | 10 000 | National | Sometimes | 119055325391 |
| We are advocating for the inclusion of immunotherapy for early-stage triple-negative breast cancer patients within the reimbursement coverage of the National Health Insurance scheme. | Рак
> Рак: молочная железа | Улучшение путей доступа
> Обеспечение равного доступа к лекарствам/медицинской помощи | 10 000 | National | Regularly | 119016883314 |
| Advocating for the expansion of reimbursement coverage for new medicines to encompass broader indications. | Рак
> Рак: нейроэндокринный (НЭО) | Улучшение путей доступа
> Обеспечение равного доступа к лекарствам/медицинской помощи | 100 | National | Sometimes | 119051407743 |
| We communicate patient needs to the National Health Insurance Administration in order to improve patient access to treatment. | Нервно-мышечный
> Спинальная мышечная атрофия (СМА) | Улучшение путей доступа
> Обеспечение равного доступа к лекарствам/медицинской помощи | 100 | National | Regularly | 119053648739 |
| In advocating for patient rights and access to new medicines, we engage with stakeholders, government authorities, and relevant experts to communicate patients' clinical needs and the urgency of treatment. | Рак
> Рак: большинство видов | Улучшение путей доступа
> Обеспечение равного доступа к лекарствам/медицинской помощи | 10 000 | National | Sometimes | 119055308347 |
| Convene an annual year-end review bringing together regulatory authorities, cancer patient advocacy organisations, and clinical physicians to evaluate the NHI reimbursement policies for that calendar year. Patient advocacy groups present on unmet patient needs, clinicians conduct a cancer-type-specific assessment of the gaps between Taiwan's NHI [全民健康保險 – National Health Insurance] reimbursement coverage and oncology treatment guidelines, and dialogue is facilitated with the regulatory authorities. | Рак
> Рак: большинство видов | Доказательный вклад пациента
> Используйте данные о пациентах для принятия решений | 5 000 | National | Sometimes | 119022421395 |
| We serve as members of the Infected Persons Rights Protection Committee under Taiwan CDC [Centers for Disease Control]. | ВИЧ
> ВИЧ | Институциональное управление
> Обеспечить представительство в государственных консультативных органах | 5 000 | National | Regularly | 119021698989 |
| In advocating for patient rights and access to new medicines, we engage with stakeholders, government authorities, and relevant experts to communicate patients' clinical needs and the urgency of treatment. | Рак
> Рак: большинство видов | Институциональное управление
> Эффективная работа в многосторонних сетях заинтересованных сторон | 10 000 | National | Sometimes | 119055308347 |
взаимодействия
действия и защита интересов
5 упоминания
